BIOPIX-T

Executive Summary

BIOPIX-T is a privately held medical device company headquartered in Grenoble, France, specializing in the design and manufacture of molecular diagnostic devices for point-of-care (POC) applications. Founded in 2019, the company has developed its flagship product, the Pebble, a compact POC molecular diagnostic platform aimed at delivering rapid, accurate test results outside traditional laboratory settings. As a certified manufacturer, BIOPIX-T is positioned to address the growing demand for decentralized diagnostics in infectious disease, antimicrobial resistance, and other high-need areas. The company's focus on miniaturization and ease-of-use aligns with the broader industry shift toward accessibility and speed in diagnostics. However, with limited publicly available information on funding, revenue, or commercial traction, BIOPIX-T appears to be in an early commercial or developmental stage. The company's success will depend on achieving regulatory clearances, establishing manufacturing scale, and securing distribution partnerships in the competitive POC diagnostics landscape. Its European base may offer advantages in terms of regulatory pathways (CE marking) and access to EU markets, but global expansion will require strategic validation.

Upcoming Catalysts (preview)

• Q4 2026CE Marking or Regulatory Clearance for Pebble Platform60% success
• TBDStrategic Partnership or Distribution Agreement for European Market50% success
• Q2 2026Completion of Clinical Validation Study for Lead Assay70% success